REG - Destiny Pharma PLC - Notice of XF Pipeline Update Meeting

Destiny PharmaAnnouncement

27/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230927:nRSa7313Na&default-theme=true

RNS Number : 7313N  Destiny Pharma PLC  27 September 2023

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Notice of XF Pipeline Update Meeting

 

Brighton, United Kingdom - 27 September 2023 - Destiny Pharma plc
(AIM:DEST), a clinical stage biotechnology company focused on the development
and commercialisation of novel medicines to prevent life threatening
infections, today announces that it will host a meeting for analysts and
investors on its XF product pipeline on Tuesday, 17 October 2023 at 2:00pm BST
/ 9:00am EDT.

 

The meeting will be held in person at the offices of Cavendish, 1 Bartholomew
Close, London, EC1A 7BL, alongside the option of virtual attendance via the
Investor Meet platform.

 

The meeting, which is scheduled to last around two hours, will be led by Chris
Tovey, Chief Executive Officer, and will feature presentations from the
management team on the products and potential of the XF product pipeline. The
meeting will also feature discussions from external speakers as follows:

 

·      Professor Mark Wilcox, Consultant Microbiologist and Head of
R&D in Microbiology at the Leeds Teaching Hospital and member of Destiny
Pharma's Scientific Advisory Board: Presentation of the issue of surgical site
infections and its impact on the healthcare system and patients

 

·      Dr Alex Mericli, Associate Professor and Plastic Surgeon at MD
Anderson Cancer Center and Mr Raghbir Khakha, Consultant Trauma and
Orthopaedic Surgeon at Guy's and St Thomas's Hospital: Discussion of the
reality on the wards

 

No new material disclosures will be made during the meeting and the
presentation will be made available on the Company's website.

 

There will be an opportunity for Q&A with the speakers and Destiny
Pharma's management team.

Prior registration for the event is required. To attend in person please
contact RD@destinypharma.com (mailto:RD@destinypharma.com) .

 

To attend virtually, investors can sign up to Investor Meet Company for free,
and add to meet Destiny Pharma plc via:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
(https://www.investormeetcompany.com/destiny-pharma-plc/register-investor)

 

Investors who already follow Destiny Pharma plc on the Investor Meet Company
platform will automatically be invited to the event.

 

 

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0) 127 370 4440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

Powerscourt Group

Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward

+44 (0) 20 7250 1446

Destiny@powerscourt-group.com (mailto:Destiny@powerscourt-group.com)

 

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash / George Dollemore, Corporate Finance

Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

 

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development pipeline includes
two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical staphylococcal
hospital infections including MRSA.

 

 

For further information on the Company, please visit www.destinypharma.com
(https://url.avanan.click/v2/___http:/www.destinypharma.com___.YXAxZTpzaG9yZWNhcDphOm86MTUzZTZjNTdkOGU2YTA4YmVjZDAzYzcwMmJmODM0ODk6NjozZThjOjBmMDE5MWJiMjJkOWNlOGRjY2RlMzE3MGMzNGEwZDBjMDJlMmMwNmI3ZmMzYjZiMWY3MjM4MDA2N2ZjM2Y5YTE6cDpU)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGFLFEEATIRFIV